

## Autoimmunité et Inflammation

Vincent Aubert

### Références

1. Boissier MC, Assier E, Falgarone G, Bessis N. Du déséquilibre de la balance Th1–Th2 à celui de la balance Th17-Treg : évolution du paradigme de la polyarthrite rhumatoïde. *Rev Rhum.* 2008;75:555-7.
2. Kim B-S, Park Y-J, Chung Y. Targeting IL-17 in autoimmunity and inflammation. *Arch Pharm Res.* 2016;39:1537-47.
3. Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases. *Mediators of Inflammation.* 2017; Article ID 3908061, 11 pages.
4. Tracy A, Buckley CD, Raza K. Pre-symptomatic autoimmunity in rheumatoid arthritis :when does the disease start ? *Sem Immunopathol.* 2017;DOI 10.1007/s00281-017-0620-6
5. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani L, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti- TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. *Ann Rheum Dis.* 2004;Oct;63(10):1218-21.
6. Iannone F, Tampoia M, Giannini M, Lopalco G, Cantarini L, Villalta C, et al. Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. *Clin Exp Rheumatol.* 2016;34(3):424-9.
7. Lv Q, Yin Y, Li X, Shan G, Wu X, Liang D, et al. The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNFa Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis. *PLoS ONE* 2014;9(2):e89442. doi:10.1371/journal.pone.0089442.